Pruritus

Patients on hemodialysis with pruritus who received a difelikefalin injection experienced reduced itch intensity, according to phase 3 trial results from the KALM-2 study.

Patients with both pruritus and chronic kidney disease stages 3 to 5 experienced reduced itch intensity at 12 weeks after treatment with oral difelikefalin compared with placebo, according to phase 2 trial results presented at the virtual National Kidney Foundation Spring Clinical Meetings.

Inclisiran, an investigational cholesterol-lowering therapy, reduced LDL in high-risk patients with atherosclerotic CVD and in those with heterozygous familial hypercholesterolemia, or FH, according to data from the ORION-10 and ORION-9 trials, respectively.

Mirum Pharmaceuticals completed a clinical pre-new drug application meeting with the FDA for maralixibat, the company’s therapeutic candidate for the treatment of Alagille syndrome-associated pruritus, according to a press release.

Results from the phase 2 ATLAS study showed that neither monotherapy nor combined therapy with cilofexor reached the endpoint of significant improvement in fibrosis stage without worsening of nonalcoholic steatohepatitis, according to a press release from Gilead Sciences.

BOSTON — Maralixibat demonstrated durable control of serum bactericidal antibody, pruritus, and xanthoma in children with Alagille syndrome, according to data from the ICONIC study presented at The Liver Meeting 2019.

WASHINGTON — Difelikefalin significantly reduced itch intensity and was linked to an increase in quality of life for patients on hemodialysis who had moderate to severe pruritus, according to phase 3 data presented at ASN Kidney Week.

Phase 3 data presented at the European Academy of Dermatology and Venereology Congress demonstrated that treatment with Taltz resulted in a 75% improvement in Psoriasis Area of Severity Index score and static Physician Global Assessment of clear or almost clear skin at 12 weeks in pediatric patients with moderate to severe plaque psoriasis.

Bermekimab, which neutralizes interleukin-1 alpha, improved all disease measures of atopic dermatitis, including a large reduction in pruritus, according to phase 2 trial results presented at the European Academy of Dermatology and Venereology Congress by Alice Gottlieb, MD, PhD, of Icahn School of Medicine at Mount Sinai.

Ingenol mebutate gel 0.027% was superior to vehicle treatment for actinic keratosis on the face, scalp and chest with areas 250 cm2.